Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-07-06T05:49:15.676Z Has data issue: false hasContentIssue false
  • English
  • Français

Balancing risks and benefits: nuisance medication and cognitive decline in late-life

Commentary on “Benzodiazepine use and risk of incident MCI and dementia in a community sample” by Teverovsky et al.

Published online by Cambridge University Press:  15 June 2023

Jordan F. Karp ,
Matthew Erisman  and
Jasmine Singh
Jordan F. Karp*
Affiliation:
Department of Psychiatry, College of Medicine – Tucson, University of Arizona, Tucson, AZ, USA
Matthew Erisman
Affiliation:
Department of Psychiatry, College of Medicine – Tucson, University of Arizona, Tucson, AZ, USA
Jasmine Singh
Affiliation:
Department of Psychiatry, College of Medicine – Tucson, University of Arizona, Tucson, AZ, USA
*
Email: karpjf@arizona.edu
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Commentary
Information
International Psychogeriatrics , Volume 36 , Special Issue 2: Issue Theme: Psycho-Bio-Social Risk Factors and Dementia , February 2024 , pp. 89 - 91
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of International Psychogeriatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

2023 American Geriatrics Society Beers Criteria® Update Expert Panel. (2023). American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. Journal of the American Geriatrics Society. https://doi.org/10.1111/jgs.18372. Advance online publication.Google Scholar
Alzheimer’s Association Report. (2023). 2023 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 19, 1598–1695. https://doi.org/10.1002/alz.13016 CrossRefGoogle Scholar
de Almondes, K. M., Costa, M. V., Malloy-Diniz, L. F. and Diniz, B. S. (2016). Insomnia and risk of dementia in older adults: systematic review and meta-analysis. Journal of Psychiatric Research, 77, 109–115. https://doi.org/10.1016/j.jpsychires.2016.02.021 CrossRefGoogle ScholarPubMed
Gallacher, J., Elwood, P., Pickering, J., Bayer, A., Fish, M. and Ben-Shlomo, Y. (2012). Benzodiazepine use and risk of dementia: evidence from the Caerphilly Prospective Study (CaPS). Journal of Epidemiology and Community Health, 66, 869–873. https://doi.org/10.1136/jech-2011-200314 CrossRefGoogle ScholarPubMed
Gallagher, D., Kiss, A., Lanctot, K. and Herrmann, N. (2018). Depression and risk of Alzheimer dementia: a longitudinal analysis to determine predictors of increased risk among older adults with depression. The American Journal of Geriatric Psychiatry, 26, 819–827. https://doi.org/10.1016/j.jagp.2018.05.002 CrossRefGoogle ScholarPubMed
Gray, S. L. et al. (2015). Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Internal Medicine, 175, 401–407. https://doi.org/10.1001/jamainternmed.2014.7663 CrossRefGoogle ScholarPubMed
Gulpers, B., Ramakers, I., Hamel, R., Köhler, S., Oude Voshaar, R. and Verhey, F. (2016). Anxiety as a predictor for cognitive decline and dementia: a systematic review and meta-analysis. The American Journal of Geriatric Psychiatry, 24, 823–842. https://doi.org/10.1016/j.jagp.2016.05.015 CrossRefGoogle ScholarPubMed
Jang, J. Y., Ho, J. K., Blanken, A. E., Dutt, S. and Nation, D. A. (2020). Affective neuropsychiatric symptoms as early signs of dementia risk in older adults. Journal of Alzheimer’s Disease, 77, 1195–1207. https://doi.org/10.3233/jad-200190 CrossRefGoogle ScholarPubMed
Levine, S. Z., Rotstein, A., Goldberg, Y., Reichenberg, A. and Kodesh, A. (2023). Opioid exposure and the risk of dementia: a national cohort study. The American Journal of Geriatric Psychiatry, 31, 315–323. https://doi.org/10.1016/j.jagp.2022.05.013 CrossRefGoogle ScholarPubMed
Livingston, G. et al. (2020). Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet, 396, 413–446. https://doi.org/10.1016/S0140-6736(20)30367-6 CrossRefGoogle ScholarPubMed
Nafti, M., Sirois, C., Kröger, E., Carmichael, P. H. and Laurin, D. (2020). Is benzodiazepine use associated with the risk of dementia and cognitive impairment-not dementia in older persons? The Canadian Study of Health and Aging. Annals of Pharmacotherapy, 54, 219–225. https://doi.org/10.1177/1060028019882037 CrossRefGoogle ScholarPubMed
Petersen, R. C. et al. (2018). Practice guideline update summary: mild cognitive impairment: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology, 90, 126–135. https://doi.org/10.1212/WNL.0000000000004826 CrossRefGoogle Scholar
Rajan, K. B., Weuve, J., Barnes, L. L., McAninch, E. A., Wilson, R. S. and Evans, D. A. (2021). Population estimate of people with clinical Alzheimer’s disease and mild cognitive impairment in the United States (2020-2060). Alzheimer’s & Dementia, 17, 1966–1975. https://doi.org/10.1002/alz.12362 CrossRefGoogle ScholarPubMed
Teverovsky, E. G., Gildengers, A., Ran, X., Jacobsen, E., Chang, C. H. and Ganguli, M. (2023). Benzodiazepine use and risk of incident MCI and dementia in a community sample. International Psychogeriatrics, 1–7. https://doi.org/10.1017/S1041610223000455 Google Scholar
Zhao, W., Zhao, L., Chang, X., Lu, X. and Tu, Y. (2023). Elevated dementia risk, cognitive decline, and hippocampal atrophy in multisite chronic pain. Proceedings of the National Academy of Sciences of the United States of America, 120, e2215192120. https://doi.org/10.1073/pnas.2215192120 CrossRefGoogle ScholarPubMed